Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Alessio CortelliniAndrea De GiglioKatia CannitaDiego L CortinovisRobin CornelissenCinzia BaldessariRaffaele GiustiEttore D'ArgentoFrancesco GrossiMatteo SantoniAnnamaria CatinoRossana BerardiVincenzo SforzaGiovanni RossiLorenzo AntonuzzoVincenzo Di NoiaDiego SignorelliAlain GelibterMario Alberto OcchipintiAlessandro FolladorFrancesca RastelliRita ChiariLuigi Della GravaraAlessandro InnoMichele De TursiPietro Di MarinoGiovanni MansuetoFederica ZorattoMarco FilettiMichele MontroneFabrizio CitarellaMaria Vittoria PensieriMarco RussanoLuca CantiniOlga NigroAlessandro LeonettiPaola BordiGabriele MinutiLorenza LandiAlessandro De TomaClelia DonisiSerena RicciardiMaria Rita MigliorinoValerio Maria NapoliGianmarco LeoneGiulio MetroGiuseppe L BannaAlex FriedlaenderAlfredo AddeoCorrado FicorellaGiampiero PorzioPublished in: Thoracic cancer (2021)
Among metastatic NSCLC patients with PD-L1 expression ≥50% receiving first-line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first-line chemotherapy.